Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
This study aims to significantly improve the acute and late morbidity of patients with oropharyngeal and laryngeal squamous cell carcinoma both by tailoring the elective irradiation only to regions with a legitimate risk of recurrence (> 5%) and by lowering the elective dose to 40 Gy. Level IB will not be electively treated unless it is involved with pathologic or suspicious lymphadenopathy. Level V will not be treated unless two or more ipsilateral nodal levels are involved (or level V itself has pathologic or suspicious adenopathy). Levels III and IV will only be irradiated if the immediately proximal level contains pathologic lymphadenopathy (i.e. level III irradiated if level II is positive; level IV irradiated if level III is positive). We anticipate that this approach should dramatically improve the acute and late complication profile.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiation Therapy | Experimental | Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intensity Modulated Radiation Therapy | Radiation | The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients With Solitary Elective Volume Recurrence | The crude risk of 2-year solitary elective volume recurrence will be calculated among all patients who are followed for at least 2 years. Patients who die before 2 years without an SEVR will be included in the denominator. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life (QOL) Patient Reported Outcomes (PRO) | Quality of life (QOL) patient-reported outcomes (PRO) for overall number of participants following treatment with elective volume and dose de-escalation, using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), EORTC HN35, which is specific to head and neck cancer, and composite MD Anderson Dysphagia Inventory (MDADI). EORTC QLQ-C30 and QLQ-H&N35 are scored on a 4-point categorical scale ranging from 1 "not at all" to 4 "very much". This scale is then linearly transformed to a 0-100 scale, where a higher score represents a higher response level. A high score for a functional scale represents higher level functioning, a high score for quality of life represents a high quality of life, and a high score for a symptom scale represents worse symptoms. MD Anderson Dysphagia Inventory (MDADI) questionnaire: Possible score ranges from 0-100, with higher score indicating higher functioning. |
Not provided
Inclusion Criteria:
Pathologically-proven diagnosis of squamous cell carcinoma of the oropharynx or larynx. Squamous cell carcinoma of unknown primary is not allowed.
Patients must have clinically or radiographically evident measureable disease at the primary site and/or nodal stations. Patients may undergo a diagnostic tonsillectomy, and diagnostic lymph node excision (< 2 nodes) is also allowable.
Clinical stage I-IVB (AJCC, 7th edition); stages I-II glottic cancer are excluded
Age ≥ 18 years.
ECOG Performance Status 0-2
Adequate organ and marrow function as defined below:
leukocytes ≥ 3,000/mcL
absolute neutrophil count ≥ 1,500/mcL
platelets ≥ 100,000/mcl
total bilirubin within normal institutional limits
AST(SGOT)/ALT(SPGT) ≤ 2.5 X institutional upper limit of normal
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential.
Neck CT and/or neck MRI, and whole body PET-CT.
Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Sher, MD, MPH | U Texas Southwestern Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rush University Medical Center | Chicago | Illinois | 60612 | United States | ||
| University of Texas Southwestern Medical Center - Dallas |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Radiation Therapy | Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). There was only one study arm. The radiation field and dose are the same with or without chemotherapy. The intent is to assess the effects of radiation therapy, regardless of chemotherapy treatment. Intensity Modulated Radiation Therapy: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction. chemotherapy: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 18, 2021 |
Not provided
Not provided
radiation therapy
Not provided
Not provided
Not provided
Not provided
|
|
| chemotherapy | Drug | chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion |
|
|
| 12 months |
| Number of Participants With Definite, Possible, and Probable Protocol-related Toxicities (Grade 3-5) | Only adverse events (grade 3-5) assessed to be definitely, probably, or possibly related to protocol treatment up to 2 years post-treatment will be considered. This was measured according to NCI's CTCAE v4.0 toxicity criteria. | 2 years |
| Total Number of Participants With Gastrostomy Dependence | The prevalence of gastrostomy use up to 2 years will be described. | 2 years |
| Patient Utilities | The average patient utilities (derived from EQ-5D) from baseline up to 2 years from the end of treatment will be described. Changes in patient utility will be analyzed using generalized estimated equations (GEE). | 2 years |
| Overall Survival | Overall survival will be calculated from the initiation of treatment using the Kaplan-Meier method. | 2 years |
| Progression-free Survival | Progression-free survival will be calculated from the initiation of treatment. Progression is confirmed by biopsy, which will be used as the date of progression. | 2 year |
| Probability of Locoregional or Distant Tumor Failure | The percentage of patients with locoregional or distant failure within 2 years of treatment will be estimated using cumulative incidence statistics, with death serving as the competing risk. Cumulative incidence refers to the estimated risk/probability of tumor failure within 2 years of treatment, either locoregional recurrence or distant metastasis, accounting for the competing risk of death. | 2 years |
| Dallas |
| Texas |
| 75390 |
| United States |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Radiation Therapy | Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) Intensity Modulated Radiation Therapy: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction. chemotherapy: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
| |||||||||||||||||||||||
| Disease site | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Patients With Solitary Elective Volume Recurrence | The crude risk of 2-year solitary elective volume recurrence will be calculated among all patients who are followed for at least 2 years. Patients who die before 2 years without an SEVR will be included in the denominator. | Posted | Count of Participants | Participants | 2 years |
|
|
| |||||||||||||||||||||||||||
| Secondary | Quality of Life (QOL) Patient Reported Outcomes (PRO) | Quality of life (QOL) patient-reported outcomes (PRO) for overall number of participants following treatment with elective volume and dose de-escalation, using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), EORTC HN35, which is specific to head and neck cancer, and composite MD Anderson Dysphagia Inventory (MDADI). EORTC QLQ-C30 and QLQ-H&N35 are scored on a 4-point categorical scale ranging from 1 "not at all" to 4 "very much". This scale is then linearly transformed to a 0-100 scale, where a higher score represents a higher response level. A high score for a functional scale represents higher level functioning, a high score for quality of life represents a high quality of life, and a high score for a symptom scale represents worse symptoms. MD Anderson Dysphagia Inventory (MDADI) questionnaire: Possible score ranges from 0-100, with higher score indicating higher functioning. | Posted | Mean | Standard Error | score on a scale | 12 months |
| ||||||||||||||||||||||||||||
| Secondary | Number of Participants With Definite, Possible, and Probable Protocol-related Toxicities (Grade 3-5) | Only adverse events (grade 3-5) assessed to be definitely, probably, or possibly related to protocol treatment up to 2 years post-treatment will be considered. This was measured according to NCI's CTCAE v4.0 toxicity criteria. | Posted | Count of Participants | Participants | 2 years |
|
| ||||||||||||||||||||||||||||
| Secondary | Total Number of Participants With Gastrostomy Dependence | The prevalence of gastrostomy use up to 2 years will be described. | Posted | Count of Participants | Participants | 2 years |
|
| ||||||||||||||||||||||||||||
| Secondary | Patient Utilities | The average patient utilities (derived from EQ-5D) from baseline up to 2 years from the end of treatment will be described. Changes in patient utility will be analyzed using generalized estimated equations (GEE). | Collected data were not considered valid due to software limitations as it was not available to auto-calculate the data as proposed by our EMR | Posted | 2 years |
|
| |||||||||||||||||||||||||||||
| Secondary | Overall Survival | Overall survival will be calculated from the initiation of treatment using the Kaplan-Meier method. | Reported the percentage of the total patient population who survived to 2 years post-treatment. | Posted | Number | percentage of patients | 2 years |
|
| |||||||||||||||||||||||||||
| Secondary | Progression-free Survival | Progression-free survival will be calculated from the initiation of treatment. Progression is confirmed by biopsy, which will be used as the date of progression. | Percentage of the total patient population with progression-free survival 2 years post treatment | Posted | Number | percentage of patients | 2 year |
|
| |||||||||||||||||||||||||||
| Secondary | Probability of Locoregional or Distant Tumor Failure | The percentage of patients with locoregional or distant failure within 2 years of treatment will be estimated using cumulative incidence statistics, with death serving as the competing risk. Cumulative incidence refers to the estimated risk/probability of tumor failure within 2 years of treatment, either locoregional recurrence or distant metastasis, accounting for the competing risk of death. | Posted | Number | percentage of patients | 2 years |
|
|
30 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Radiation Therapy | Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) Intensity Modulated Radiation Therapy: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction. chemotherapy: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion | 1 | 72 | 35 | 72 | 65 | 72 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Acute Encephalopathy | Nervous system disorders | Non-systematic Assessment |
| ||
| Acute kidney injury | Renal and urinary disorders | Non-systematic Assessment |
| ||
| acute mescenteric ischemia | Vascular disorders | Non-systematic Assessment |
| ||
| Allergic Reaction | Immune system disorders | Non-systematic Assessment |
| ||
| anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Anorexia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| aspiration | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Atypical Chest Pain | General disorders | Non-systematic Assessment |
| ||
| chills | General disorders | Non-systematic Assessment |
| ||
| Dehydration | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Delirium | Psychiatric disorders | Non-systematic Assessment |
| ||
| depression | Psychiatric disorders | Non-systematic Assessment |
| ||
| dizziness | Nervous system disorders | Non-systematic Assessment |
| ||
| dysphagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Dyspnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| fatigue | General disorders | Non-systematic Assessment |
| ||
| febrile neutropenia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| fever | General disorders | Non-systematic Assessment |
| ||
| Fracture | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Hypercapnic Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| hypernatremia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypertension | Vascular disorders | Non-systematic Assessment |
| ||
| hyponatremia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| hypotensive | Vascular disorders | Non-systematic Assessment |
| ||
| hypoxia | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Lung infection | Infections and infestations | Non-systematic Assessment |
| ||
| nausea | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Neoplasm of unknown etiology | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| Neutropenic Fever | General disorders | Non-systematic Assessment |
| ||
| Opioid Overdose | General disorders | Non-systematic Assessment |
| ||
| Oral Hemorrhage | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral Mucositis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| parethesia | Nervous system disorders | Non-systematic Assessment |
| ||
| Radiation Dermatitis | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| seizure | Nervous system disorders | Non-systematic Assessment |
| ||
| sepsis | Infections and infestations | Non-systematic Assessment |
| ||
| Severe systemic inflammatory response syndrome | General disorders | Non-systematic Assessment |
| ||
| Skin infection (cellulitis ) | Infections and infestations | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal distension | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| abdominal pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| abscess of chin | General disorders | Non-systematic Assessment |
| ||
| Acid Reflex | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| acne vulgaris | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Acneform rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| agitated | Psychiatric disorders | Non-systematic Assessment |
| ||
| Albumin Decreased | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| alkaline phosphate decreased | Investigations | Non-systematic Assessment |
| ||
| alkaline phosphatase increased | Investigations | Non-systematic Assessment |
| ||
| Allergic Reaction | Immune system disorders | Non-systematic Assessment |
| ||
| Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| alopecia | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| ALP increased | Investigations | Non-systematic Assessment |
| ||
| ALT decreased | Investigations | Non-systematic Assessment |
| ||
| ALT increased | Investigations | Non-systematic Assessment |
| ||
| altered mental status | General disorders | Non-systematic Assessment |
| ||
| altered sensation | Nervous system disorders | Non-systematic Assessment |
| ||
| Anaerobic infection | Infections and infestations | Non-systematic Assessment |
| ||
| anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Anorexia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| anxiety | Psychiatric disorders | Non-systematic Assessment |
| ||
| Aortic injury | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| aphonia | Nervous system disorders | Non-systematic Assessment |
| ||
| appetite change | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Arm pain | General disorders | Non-systematic Assessment |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Arthritis | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| aspiration | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| AST increased | Investigations | Non-systematic Assessment |
| ||
| asthenia | General disorders | Non-systematic Assessment |
| ||
| asthma | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Atrial Fibrillation | Cardiac disorders | Non-systematic Assessment |
| ||
| Atypical Chest Pain | General disorders | Non-systematic Assessment |
| ||
| AV block 1st Degree | Vascular disorders | Non-systematic Assessment |
| ||
| Azotemia | Investigations | Non-systematic Assessment |
| ||
| back pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| BCC Nose | General disorders | Non-systematic Assessment |
| ||
| bite wound | General disorders | Non-systematic Assessment |
| ||
| bladder incontinence | Renal and urinary disorders | Non-systematic Assessment |
| ||
| bleeding from mouth | General disorders | Non-systematic Assessment |
| ||
| blurred vision | Eye disorders | Non-systematic Assessment |
| ||
| Bloating | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| bloody secretion | Vascular disorders | Non-systematic Assessment |
| ||
| blurred vision | Eye disorders | Non-systematic Assessment |
| ||
| bowel incontinence | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Bradycardia | Cardiac disorders | Non-systematic Assessment |
| ||
| breast pain | Hepatobiliary disorders | Non-systematic Assessment |
| ||
| breast swelling | General disorders | Non-systematic Assessment |
| ||
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Coronary Artery Disease | Cardiac disorders | Non-systematic Assessment |
| ||
| calcium count increased | Investigations | Non-systematic Assessment |
| ||
| Cardiac troponin I increased | Investigations | Non-systematic Assessment |
| ||
| Cellulitis | Infections and infestations | Non-systematic Assessment |
| ||
| cervical stenosis of spine | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| cervicalgia | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| change in mole | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Cheilitis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Chest congestion | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| chest pain | General disorders | Non-systematic Assessment |
| ||
| chest tightness | General disorders | Non-systematic Assessment |
| ||
| chest wall pain | Cardiac disorders | Non-systematic Assessment |
| ||
| chills | General disorders | Non-systematic Assessment |
| ||
| Chronic Kidney Disease | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Cold Intolerance | General disorders | Non-systematic Assessment |
| ||
| confusion | Psychiatric disorders | Non-systematic Assessment |
| ||
| congestion | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| constipation | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| contact dermatitis | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| cough | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| creatinine decreased | Investigations | Non-systematic Assessment |
| ||
| creatinine increased | Investigations | Non-systematic Assessment |
| ||
| cystitis | Renal and urinary disorders | Non-systematic Assessment |
| ||
| decreased appetite | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Decreased platelet count | Investigations | Non-systematic Assessment |
| ||
| decreased urine output | Renal and urinary disorders | Non-systematic Assessment |
| ||
| decreased WBC | Investigations | Non-systematic Assessment |
| ||
| Dehydration | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| dental infection | Infections and infestations | Non-systematic Assessment |
| ||
| depression | Psychiatric disorders | Non-systematic Assessment |
| ||
| dermatitis | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Diabetes | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| diaphoresis | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Diarrhea | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| discoloration of tongue | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Discolored discharge | General disorders | Non-systematic Assessment |
| ||
| dizziness | Nervous system disorders | Non-systematic Assessment |
| ||
| double vision | Eye disorders | Non-systematic Assessment |
| ||
| dry cough | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| dry mouth | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Dry Skin | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Dsyphagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| DVT | Vascular disorders | Non-systematic Assessment |
| ||
| dypsnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Dysesthesia | Nervous system disorders | Non-systematic Assessment |
| ||
| dysgeusia | Nervous system disorders | Non-systematic Assessment |
| ||
| Dyspepsia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Dysphagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| dysphonia | General disorders | Non-systematic Assessment |
| ||
| dyspnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| dysuria | Renal and urinary disorders | Non-systematic Assessment |
| ||
| ear ache | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| ear congestion | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Ear disorder - other | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Ear infection | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| ear pain | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| easy bruising | Vascular disorders | Non-systematic Assessment |
| ||
| Edema | General disorders | Non-systematic Assessment |
| ||
| Edema limbs | General disorders | Non-systematic Assessment |
| ||
| elbow pain | General disorders | Non-systematic Assessment |
| ||
| elevated ANC | Investigations | Non-systematic Assessment |
| ||
| elevated bilirubin | Investigations | Non-systematic Assessment |
| ||
| elevated CO2 | Investigations | Non-systematic Assessment |
| ||
| elevated creatinine | Investigations | Non-systematic Assessment |
| ||
| Elevated prothrombin | Investigations | Non-systematic Assessment |
| ||
| elevated WBC | Investigations | Non-systematic Assessment |
| ||
| emesis | Hepatobiliary disorders | Non-systematic Assessment |
| ||
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| erythema | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| esophagitis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| eye disorder- other | Eye disorders | Non-systematic Assessment |
| ||
| Eye pain | Eye disorders | Non-systematic Assessment |
| ||
| Eye redness | Eye disorders | Non-systematic Assessment |
| ||
| Facial edema | General disorders | Non-systematic Assessment |
| ||
| Facial rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Facial swelling | General disorders | Non-systematic Assessment |
| ||
| Factor V | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Fatigue | General disorders | Non-systematic Assessment |
| ||
| Fecal incontinence | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Fever | General disorders | Non-systematic Assessment |
| ||
| Fibromyalgia | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Flank Pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Flushing | Vascular disorders | Non-systematic Assessment |
| ||
| Focal weakness | Nervous system disorders | Non-systematic Assessment |
| ||
| Foot pain | General disorders | Non-systematic Assessment |
| ||
| Fracture | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| G tube dysfunction | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| G tube placement | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Gastroesophageal reflux | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Gastrointestinal disorders - other, melena | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Gastroparesis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Generalized weakness | General disorders | Non-systematic Assessment |
| ||
| GERD | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Gingival ulceration | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Hair loss | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Hallucinations | Psychiatric disorders | Non-systematic Assessment |
| ||
| Headache | Nervous system disorders | Non-systematic Assessment |
| ||
| Hearing impaired | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Hearing loss | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Heartburn | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Heat intolerance | General disorders | Non-systematic Assessment |
| ||
| Hematochezia (rectal bleeding) | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Hematuria | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Hemoptysis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Hemorrhoidal hemorrhage | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Hernia | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Hiccups | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| High cholesterol | Investigations | Non-systematic Assessment |
| ||
| Hip pain | General disorders | Non-systematic Assessment |
| ||
| Hoarseness | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Hot flashes | Vascular disorders | Non-systematic Assessment |
| ||
| Hypochloride | Investigations | Non-systematic Assessment |
| ||
| Hypercalcemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyperchloride | Investigations | Non-systematic Assessment |
| ||
| Hyperglycemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyperkalemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyperlipidemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypernatremia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyperphosphatemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyperpigmentation | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Hypersalivation | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Hypertension | Vascular disorders | Non-systematic Assessment |
| ||
| Hyperthyroid | Endocrine disorders | Non-systematic Assessment |
| ||
| Hypoalbuminemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypocalcemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypochloremia | Investigations | Non-systematic Assessment |
| ||
| Hypoglycemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypokalemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypomagnesemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hyponatremia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypophosphatemia | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Hypophosphorous | Investigations | Non-systematic Assessment |
| ||
| Hypotension | Vascular disorders | Non-systematic Assessment |
| ||
| Hypothyroidism | Endocrine disorders | Non-systematic Assessment |
| ||
| Hypoxia | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Infection | Infections and infestations | Non-systematic Assessment |
| ||
| Infections and infestations - other, COVID-19 | Infections and infestations | Non-systematic Assessment |
| ||
| Inflammation | General disorders | Non-systematic Assessment |
| ||
| Influenza (flu-like symptoms) | Infections and infestations | Non-systematic Assessment |
| ||
| Infusion related reaction | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Injury, other, (mild fall injury) | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Insomnia | Psychiatric disorders | Non-systematic Assessment |
| ||
| Itching | General disorders | Non-systematic Assessment |
| ||
| Jaw Pain | General disorders | Non-systematic Assessment |
| ||
| Jaw Spasm | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Joint pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Knee pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| L Elbow Pain | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| L knee pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Laryngeal Inflammation | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Laryngeal Edema | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Laryngitis | Infections and infestations | Non-systematic Assessment |
| ||
| LE edema | General disorders | Non-systematic Assessment |
| ||
| Leukocytosis | Investigations | Non-systematic Assessment |
| ||
| Leukopenia | Investigations | Non-systematic Assessment |
| ||
| Leukoplakia | General disorders | Non-systematic Assessment |
| ||
| Localized edema | General disorders | Non-systematic Assessment |
| ||
| Loss of smell | General disorders | Non-systematic Assessment |
| ||
| Low total protein | General disorders | Non-systematic Assessment |
| ||
| Lower extremity pain | General disorders | Non-systematic Assessment |
| ||
| Lumbar stenosis | Nervous system disorders | Non-systematic Assessment |
| ||
| Lump on abdomen | General disorders | Non-systematic Assessment |
| ||
| Lung infection | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Lymphadenopathy | General disorders | Non-systematic Assessment |
| ||
| Lymphadema | General disorders | Non-systematic Assessment |
| ||
| Lymphocyte count decreased | Investigations | Non-systematic Assessment |
| ||
| Macular rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Mediastinal fistula | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Memory loss | Nervous system disorders | Non-systematic Assessment |
| ||
| Mental confusion | Psychiatric disorders | Non-systematic Assessment |
| ||
| Middle-ear infection | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Migraines | General disorders | Non-systematic Assessment |
| ||
| Mild odynophagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Mouth pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Mouth sores | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Mucosal infection | Infections and infestations | Non-systematic Assessment |
| ||
| Mucositis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Muscle spasm | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Musculoskeletal disorder - other | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Myalgias | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Neck edema | General disorders | Non-systematic Assessment |
| ||
| Neck pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Neoplasms benign - other | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| Nervous system disorder - other | Nervous system disorders | Non-systematic Assessment |
| ||
| Neuropathy | Nervous system disorders | Non-systematic Assessment |
| ||
| Neutropenia | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Neutrophil count decreased | Investigations | Non-systematic Assessment |
| ||
| Neutrophil count increased | Investigations | Non-systematic Assessment |
| ||
| Night sweats | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Nocturia | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Nocturnal "sweats" | General disorders | Non-systematic Assessment |
| ||
| Non-cardiac chest pain | General disorders | Non-systematic Assessment |
| ||
| Nose bleeds | General disorders | Non-systematic Assessment |
| ||
| Obesity | Metabolism and nutrition disorders | Non-systematic Assessment |
| ||
| Odynophagia | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral dysesthesia | Nervous system disorders | Non-systematic Assessment |
| ||
| Oral hemorrhage | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral lesions | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral mucositis | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Oral thrush | Infections and infestations | Non-systematic Assessment |
| ||
| Oropharyngeal edema | General disorders | Non-systematic Assessment |
| ||
| Orthopnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Otalgia | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Otic pain (L ear) | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Overdose | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Pain | General disorders | Non-systematic Assessment |
| ||
| Pain in extremity | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Pain of skin | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Pallor | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Palpitations | Cardiac disorders | Non-systematic Assessment |
| ||
| Papulopustular rash | Infections and infestations | Non-systematic Assessment |
| ||
| Parathesia | Nervous system disorders | Non-systematic Assessment |
| ||
| Peripheral neuropathy | Nervous system disorders | Non-systematic Assessment |
| ||
| Peripheral sensory neuropathy | Nervous system disorders | Non-systematic Assessment |
| ||
| Phlebitis | Vascular disorders | Non-systematic Assessment |
| ||
| Photophobia | Eye disorders | Non-systematic Assessment |
| ||
| Platelet count decreased | Investigations | Non-systematic Assessment |
| ||
| Platelet count increased | Investigations | Non-systematic Assessment |
| ||
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Polydipsia | General disorders | Non-systematic Assessment |
| ||
| Productive cough | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Pruritus | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Pulmonary embolism | Vascular disorders | Non-systematic Assessment |
| ||
| R Otalgia | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Radiation dermatitis | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Radiation ulceration | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Rash acneiform | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Rash maculo-papular | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| rectal bleeding | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| rectal fissue | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Rectal pain | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Red eyes | Eye disorders | Non-systematic Assessment |
| ||
| Reflux | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Bladder prolapse | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Respiratory disorder- other | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Rhonchus | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Rib pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Right arm pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Right chin pain | General disorders | Non-systematic Assessment |
| ||
| Right ear pain | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Right eye pain | Eye disorders | Non-systematic Assessment |
| ||
| Right inguinal hernia | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Right jaw pain | General disorders | Non-systematic Assessment |
| ||
| Saliva pooling | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Salivary duct inflammation | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Salivary inflammation | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Scoliosis | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Seasonal allergies | General disorders | Non-systematic Assessment |
| ||
| Sensory change | General disorders | Non-systematic Assessment |
| ||
| Sexual dysfunction | Reproductive system and breast disorders | Non-systematic Assessment |
| ||
| Shortness of breath | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Shoulder pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Sinus pressure | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Sinus tachycardia | Cardiac disorders | Non-systematic Assessment |
| ||
| Sinusitis | Infections and infestations | Non-systematic Assessment |
| ||
| Skin lesion | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin disorder- other | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin erythema | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin hyperpigmentation | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin infection | Infections and infestations | Non-systematic Assessment |
| ||
| Skin pigmentation | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Skin ulceration | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Sleep apnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Snoring | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Sore throat | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Speech change | General disorders | Non-systematic Assessment |
| ||
| Stoma site infection | Infections and infestations | Non-systematic Assessment |
| ||
| Stomal pain | General disorders | Non-systematic Assessment |
| ||
| Stridor | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Surgical Procedure - other | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Syncope | Nervous system disorders | Non-systematic Assessment |
| ||
| Syncopal | Nervous system disorders | Non-systematic Assessment |
| ||
| Tachycardia | Cardiac disorders | Non-systematic Assessment |
| ||
| Tachypnea | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Telangiectasia | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Thick saliva | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Thick secretions | General disorders | Non-systematic Assessment |
| ||
| Throat pain | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Thrush | Infections and infestations | Non-systematic Assessment |
| ||
| Tinnitus | Ear and labyrinth disorders | Non-systematic Assessment |
| ||
| Toothache | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Total bilirubin elevated | Investigations | Non-systematic Assessment |
| ||
| Total protein decreased | Investigations | Non-systematic Assessment |
| ||
| Tracheitis | Infections and infestations | Non-systematic Assessment |
| ||
| Tremors | Nervous system disorders | Non-systematic Assessment |
| ||
| Trismus | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| TSH elevated | Investigations | Non-systematic Assessment |
| ||
| Tumor pain | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| Ulceration | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Urinary frequency | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Urinary incontinence | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Urinary retention | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Urinary tract infection | Infections and infestations | Non-systematic Assessment |
| ||
| Urinary urgency | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Urine output decreased | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Velopharyngeal insufficiency (VPI) | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Voice alteration | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Vomiting | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Weakness | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Weight gain | Investigations | Non-systematic Assessment |
| ||
| Weight loss | Investigations | Non-systematic Assessment |
| ||
| wheezing | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| White blood cell count increased | Investigations | Non-systematic Assessment |
| ||
| White blood cell count decreased | Investigations | Non-systematic Assessment |
| ||
| Wound complication | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| Xerostomia | Gastrointestinal disorders | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. David Sher | University of Texas Southwestern Medical Center | 214/645-7607 | david.sher@utsouthwestern.edu |
| Nov 17, 2021 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D002294 | Carcinoma, Squamous Cell |
| D009062 | Mouth Neoplasms |
| D010610 | Pharyngeal Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D018307 | Neoplasms, Squamous Cell |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D010039 | Otorhinolaryngologic Neoplasms |
| D010608 | Pharyngeal Diseases |
| D010038 | Otorhinolaryngologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D050397 | Radiotherapy, Intensity-Modulated |
| D004358 | Drug Therapy |
| D002945 | Cisplatin |
| D000068818 | Cetuximab |
| ID | Term |
|---|---|
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided
| Hispanic |
|
| Other |
|
| OG001 | Total Cohort 3 Month | Total cohort |
| OG002 | Total Cohort 6 Month | Total cohort |
| OG003 | Total Cohort 12 Month | Total cohort |
|
|
|
|
|
|
|